Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Shridar Ganesan

Rbhs Cancer Institute of New Jersey, Department: None

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Ibris Inc

Disclosed Value
Listed Reason
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

Equity Interest: Dr. Ganesan holds equity interest in, is co-founder of and consultant for a start-up company (IBRIS Inc.) that is developing technology for quick and economical analysis of tissue from breast cancer biopsies, to predict how aggressive a common form of breast cancer is likely to be. The company does not have any value at this time. IBRIS Inc also holds patents on methods for image analysis of histology of ER+ breast cancers for prognosis. These patents do not have any IP value at this time. Since one of the patents contains language that includes analysis of tissue microarrays and the current study will use tissue arrays to assess expression patterns in various types of tissue, the ICOI Committee concluded that there was the perception of a conflict of interest on the part of Dr. Ganesan.

Listed Research Project
Image Mining for Comparative Analysis of Expression Patterns in Tissue Microarray

PROJECT NARRATIVE: During the first phase of this research project our team successfully designed, developed and evaluated (a) a library of analytical and computational tools for performing automated registration, segmentation, feature extraction, and classification of imaged microtissue samples; (b) data models and grid-enabled tools for performing large-scale indexing, organizing, and archiving imaged microscopy specimens and experimental results; (c) query capabilities to support reliable identification and retrieval of those imaged tissue samples from within distributed, 'gold-standard' archives of consensus-graded cases which exhibit staining and expression signatures which are most similar to those of a given query; and (d) methods and resources to support seamless, high-throughput analyses of specimens. The overarching goals of this renewal application are to build upon progress made in the first phase of the project by developing and evaluating a new family of multi-stage, searching algorithms to facilitate quick, reliable interrogation of large-scale, clinical and research, microscopy applications including whole-slide imaging and tissue microarray; developing and evaluating a suite of high-throughput services capable of automatically detecting, archiving and indexing user-specified objects (e.g. tissues, cells) in large collections of images and implement extensions to the data models and support for optimized pipeline selection. These capabilities will enable large-scale correlative outcomes studies and support expansion of the 'gold-standard' image archives and correlated clinical repositories. The services will take advantage of state-of-the-art parallel CPU-GPU machines and the searching algorithms described in Aim 1; optimizing the imaging, computational and content-based image retrieval algorithms and tools using a wide range of different tissues, cancer types and biomarkers to support clinical and research experiments and studies involving patient stratification, quality-control, and outcomes assessment; and deploying the analytical tools, data models, user-centered interfaces and reference libraries of imaged specimens to participating adopter sites to conduct open-set usability and performance studies and make these resources available to the clinical and research communities as open source software and resources to support future development and testing of new hypotheses, algorithms and methods.

Filed on September 28, 2015.

Tell us what you know about Shridar Ganesan's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

Name Institution Type Company Disclosed Value
Shridar Ganesan Rbhs Cancer Institute of New Jersey Conflict of Interest IBRIS Inc. $0 - $4,999
Shridar Ganesan Case Western Reserve University Conflict of Interest Inspirata, Inc. Value cannot be readily determined
Shridar Ganesan Rbhs Cancer Institute of New Jersey Conflict of Interest Inspirata Inc $40,000 - $59,999
Shridar Ganesan Rbhs Cancer Institute of New Jersey Conflict of Interest Rutgers, The State University of New Jersey Value cannot be readily determined
Shridar Ganesan Rutgers, the State Univ of n.j. Conflict of Interest Rutgers, The State University of New Jersey Value cannot be readily determined
Shridar Ganesan Rutgers, the State Univ of n.j. Conflict of Interest Ibris Inc Value cannot be readily determined
Shridar Ganesan Case Western Reserve University Conflict of Interest Inspirata, Inc. $60,000 - $79,999
If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page